Table 1.
Demographic, clinical, and hormonal characteristics of the obese women with fibromyalgia syndrome included in the study.
| Parameter | All data | IGF-1 SDS > −2 | IGF-1 SDS < −2 |
|---|---|---|---|
| Number | 16 | 12 | 4 |
| Age (yrs) | 36.5 ± 10.4 | 36.5 ± 10.5 | 36.8 ± 11.8 |
| BMI (kg/m2) | 43.6 ± 6.2 | 41.8 ± 4.2 | 48.9 ± 8.8∗ |
| Waist (cm) | 126.4 ± 11.1 | 123.9 ± 9.9 | 134.0 ± 12.6 |
| Hip (cm) | 133.8 ± 13.1 | 131.1 ± 6.4 | 141.8 ± 24.5 |
| Fat mass (kg) | 61.6 ± 12.9 | 58.6 ± 8.2 | 70.6 ± 19.8 |
| Fat mass (%) | 54.1 ± 4.7 | 53.0 ± 4.4 | 57.2 ± 4.6 |
| Fat-free mass (kg) | 51.6 ± 4.2 | 51.5 ± 3.6 | 51.7 ± 6.3 |
| Fat-free nass (%) | 46.0 ± 4.7 | 47.0 ± 4.4 | 42.8 ± 4.6 |
| Tender-point score | 14.7 ± 1.6 | 14.5 ± 1.5 | 15.3 ± 1.9 |
| ESR (mm/h) | 33.9 ± 18.7 | 34.8 ± 19.5 | 31.5 ± 18.7 |
| CRP (mg/dl) | 1.2 ± 1.2 | 0.9 ± 0.8 | 2.1 ± 2.1 |
| IGF-1 (ng/ml) | 138.1 ± 71.0 | 160.7 ± 66.2 | 70.5 ± 31.2∗ |
| IGF-1 SDS | −1.1 ± 0.9 | −0.7 ± 0.7 | −2.3 ± 0.1∗ |
| Peak GH (ng/ml) | 10.4 ± 5.2 | 11.7 ± 5.0 | 6.7 ± 4.5 |
| GH AUC (ng × min/ml) | 716.7 ± 392.4 | 812.8 ± 391.4 | 428.3 ± 245.6∗ |
∗ p < 0.05 versus group with IGF-1 SDS > −2. BMI: body mass index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; IGF-1: insulin-like growth factor 1; GH: growth hormone; AUC: area under the curve.